Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Kwok CW, Treeck O, Buchholz S, Seitz S, Ortmann O, Engel JB

Targeted oncology9 Oct 2014Cited by 17 (Europe PMC)

PMID25293576DOI10.1007/s11523-014-0340-yPepBankPUB-25293576

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In MDA-MB-231 breast cancer cells, triptorelin had a cytotoxic EC50 of 31.21 ± 0.21, with units unstated.
In plain wordsIn cells, triptorelin showed cytotoxic activity against MDA-MB-231 breast cancer cells.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableCytotoxic EC50 in MDA-MB-231
Study
humann: not reported in source
MDA-MB-231 TNBC cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
EC50
31.21 not reported
MDA-MB-231
Source sentences
Summary
MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH on messenger (m)RNA and protein level and were found sensitive to triptorelin with a respective median effective concentration (EC50) of 31.21 ± 0.21 and 58.50 ± 19.50.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
Report a problemFND-2529357601
02LabIn vitro (cells)Activity measurement
In HCC1806 breast cancer cells, triptorelin had a cytotoxic EC50 of 58.50 ± 19.50, with units unstated.
In plain wordsIn cells, triptorelin showed cytotoxic activity against HCC1806 breast cancer cells.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableCytotoxic EC50 in HCC1806
Study
humann: not reported in source
HCC1806 TNBC cells
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
EC50
58.5 not reported
HCC1806
Source sentences
Summary
MDA-MB-231 and HCC1806 TNBC cells both expressed receptors for GnRH on messenger (m)RNA and protein level and were found sensitive to triptorelin with a respective median effective concentration (EC50) of 31.21 ± 0.21 and 58.50 ± 19.50.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
Report a problemFND-2529357602

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

03LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cells)Activity measurement
In TNBC cells, triptorelin combined with cisplatin produced synergistic effects.
In plain wordsIn cells, triptorelin and cisplatin produced a synergistic effect together.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSynergy with cisplatin
Study
humann: not reported in source
TNBC cell lines
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Synergistic effects occurred when triptorelin was combined with cisplatin.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2529357603
04LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cells)Activity measurement
In HCC1806 cells, triptorelin combined with perifosine produced synergy.
In plain wordsIn cells, triptorelin and perifosine produced a synergistic effect together.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSynergy with perifosine
Study
humann: not reported in source
HCC1806 TNBC cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In HCC1806 cells, synergy occurred when triptorelin was applied with PI3K/AKT inhibitors perifosine and AEZS-129.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2529357604
05LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cells)Activity measurement
In HCC1806 cells, triptorelin combined with AEZS-129 produced synergy.
In plain wordsIn cells, triptorelin and AEZS-129 produced a synergistic effect together.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSynergy with AEZS-129
Study
humann: not reported in source
HCC1806 TNBC cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In HCC1806 cells, synergy occurred when triptorelin was applied with PI3K/AKT inhibitors perifosine and AEZS-129.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2529357605
06LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cells)Activity measurement
In MDA-MB-231 cells, triptorelin combined with AEZS-134 produced synergy.
In plain wordsIn cells, triptorelin and AEZS-134 produced a synergistic effect together.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSynergy with AEZS-134
Study
humann: not reported in source
MDA-MB-231 TNBC cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In MDA-MB-231 cells, synergy was observed after co-treatment with triptorelin and ERK inhibitor AEZS-134 and dual PI3K/ERK inhibitor AEZS-136.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2529357606
07LabNot a test of Triptorelin (Trelstar, Decapeptyl) aloneIn vitro (cells)Activity measurement
In MDA-MB-231 cells, triptorelin combined with AEZS-136 produced synergy.
In plain wordsIn cells, triptorelin and AEZS-136 produced a synergistic effect together.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSynergy with AEZS-136
Study
humann: not reported in source
MDA-MB-231 TNBC cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In MDA-MB-231 cells, synergy was observed after co-treatment with triptorelin and ERK inhibitor AEZS-134 and dual PI3K/ERK inhibitor AEZS-136.
1 context sentence(design, population, supporting numbers)
Summary · context
The current study investigates cytotoxic activity of triptorelin as a monotherapy and in treatment combinations with chemotherapeutic agents and inhibitors of the PI3K and the ERK pathways in in vitro models of triple negative breast cancers (TNBC).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2529357607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Summary

Results from this study7

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms